Healthtech startup Mesh Bio raises US$1.8m in seed funding

SINGAPORE-BASED Mesh Bio, a digital health startup that uses predictive analytics for the management of chronic diseases, announced on Wednesday that it has raised US$1.8 million in seed funding.

The round is led by deep tech investors Elev8.vc and SEEDS Capital, the investment arm of Enterprise Singapore. It also includes Malaysia-based Citrine Capital and private equity fund manager TAEL Partners.

The fresh funds will go into accelerating the rollout of Mesh Bio's predictive analytics and workflow automation platform, DARA, in South-east Asia. It also has plans for clinical partnerships and collaborations.

Founded in 2018, Mesh Bio said it is focused on addressing the growing clinical burden of metabolic diseases (such as diabetes) through its platform. Through analytics and automated assessments, its platform enables data-driven care, it said, which could in turn improve patient engagement and health outcomes.

The platform, DARA, draws in real-time patient data in areas such as health history, lab tests and medical images. It then delivers a patient-centric visual report to help healthcare providers in Singapore analyse patient data quickly.

Andrew Wu, co-founder and chief executive of Mesh Bio, noted that chronic diseases are on the rise in Asia, making patient management increasingly complex and challenging. "The situation is compounded by the lack of doctors, especially specialists, forcing general practitioners - who lack specialist training in endocrinology - to manage these challenging patient cases.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL

"Our vision is to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region."

Mesh Bio's predictive analytics offers a clinically validated technology to detect and support chronic diseases before they even occur, said Aditya Mathur, founder and managing director of Elev8.vc. He added: "Rapidly ageing populations across the world deserve far better healthcare."

Geoffrey Yeo, general manager of SEEDS Capital, agreed: "By enhancing clinical decision support at primary care, this could improve prevention and management of diseases such as diabetes and cardiovascular complications. We are pleased to support Mesh Bio as it ramps up the roll-out of its unique solution in Singapore and across the region."